# GHK-Cu: A Five-Decade Trail Through the Copper-Peptide Research > GHK-Cu, the copper(II) complex of glycyl-histidyl-lysine, stimulated fibroblast collagen synthesis at picomolar concentrations and modulates roughly 31% of human genes. A cited research digest. Every collagen study, skin trial and hair-count result is mapped here as a waypoint — and the honest distance still left to travel is marked plainly, never paved over. ## What the GHK-Cu literature has mapped GHK-Cu — the copper(II) complex of the tripeptide glycyl-histidyl-lysine — stimulated collagen synthesis in human fibroblast cultures starting between 10^-12 and 10^-11 M, peaked near 10^-9 M, and did so without changing cell number [1]. That dose-response is the first waypoint on a five-decade trail. The molecule is not exotic chemistry imported from a lab: it is endogenous, present in human plasma, saliva and urine, first isolated by Loren Pickart in 1973 as the plasma factor that made aged human liver tissue synthesize proteins like younger tissue [3]. The trail runs in order. Picomolar collagen synthesis in 1988 [1]. Hair-follicle stimulation in C3H mice in 1991 [13]. A measured dermal copper depot from topical application in 2011 [5]. The genome-wide gene-expression and skin-regeneration reviews of 2015 and 2018 [3][2]. A 45-patient hair-count trial in 2016 [4]. Anti-fibrosis and anti-wrinkle reviews in 2024 and 2025 [14][15]. This site walks that route study by study, marks each finding to its source, and flags the river crossings — the places where the human data runs out — rather than walking the reader past them. The headline numbers are real. Topical GHK-Cu increased collagen production in 70% of treated women, versus 50% for vitamin C and 40% for retinoic acid, in one comparative review [3]. A Connectivity Map analysis reports that GHK alters expression of about 31.2% of human genes at a 50%-or-greater change threshold [2]. The honest counterweight is equally real: there is no validated human pharmacokinetic half-life, the controlled human evidence is small and dermatologic, and a large share of the foundational literature traces to a single investigator [2]. Both belong on the same map. Read the [GHK-Cu mechanism of action](/research), the [copper peptide skin research](/skin-research), and the [copper peptide benefits](/copper-peptide-benefits) on the pages that follow. ## GHK copper peptide: what the research describes The GHK copper peptide is a copper chaperone and a pleiotropic signaling molecule at once. At picomolar-to-nanomolar concentrations it directly stimulates dermal fibroblast synthesis of collagen, elastin, glycosaminoglycans and decorin while rebalancing matrix metalloproteinases against their TIMP inhibitors [6]. The bound copper ion enables lysyl-oxidase-mediated collagen and elastin cross-linking and superoxide-dismutase-like antioxidant activity [6]. The signaling reach is broad. Wound-repair reviews report that GHK-Cu increases protein synthesis of collagen, elastin, VEGF, FGF-2, NGF and neurotrophins 3 and 4 while suppressing free radicals, thromboxane, TGF-beta-1 and TNF-alpha, and chemoattracting macrophages, mast cells and capillary cells into the repair site [6]. That same review documents the molecule across numerous models and in humans, which is why the GHK copper peptide reads less like a single-target drug and more like a coordinator of the tissue-repair program. The form matters. GHK is the free tripeptide; GHK-Cu is the copper chelate, and copper coordination is required for most of the matrix-remodeling activity in the record [3]. When a study reports an effect, the first question this digest asks is which form it used. ## What a copper peptide is A copper peptide is a short amino-acid chain that binds a copper ion through multiple coordination sites, stabilizing the metal and changing how it behaves in tissue. GHK-Cu is the canonical example: a linear glycine-histidine-lysine tripeptide chelated 1:1 to a Cu(II) ion, with molecular formula C14H23CuN6O4+ and a molecular weight of 402.92 Da [3]. The chelation is unusually tight. The GHK-Cu complex carries a copper stability constant of log K around 16.4 — far higher than the free peptide — which limits how much loose, pro-oxidant copper the complex releases [6]. That stability is part of why the copper-bound form, not the bare peptide, carries the documented bioactivity. ### What is a copper peptide? A copper peptide is a peptide that forms a high-affinity complex with copper(II) and uses that bound metal as part of its biological signal. GHK-Cu binds copper through the histidine imidazole nitrogen, the glycine alpha-amino nitrogen, and a deprotonated amide nitrogen, leaving the lysine side chain free [3]. The bound copper enables antioxidant and cross-linking chemistry the free peptide cannot reproduce [6]. ### Copper Tripeptide-1 (the INCI name) Copper Tripeptide-1 is the INCI (cosmetic-ingredient) label for GHK-Cu, the name used to declare copper-peptide content on a skincare ingredient list [3]. The research name and the formulation name describe the same molecule: Copper Tripeptide-1 on a serum carton is GHK-Cu in the literature. Topical Copper Tripeptide-1 has a long cosmetic safety record, which is one reason the skin data is the best-developed stretch of the trail. ## The age decline that started the anti-aging interest Plasma GHK falls with age. It runs at roughly 200 ng/mL (about 10^-7 M) at age 20 and declines to approximately 80 ng/mL by age 60 [3]. The regeneration reviews frame that drop as a proposed contributor to slower tissue repair with age, and it is the reason the anti-aging research thread exists at all — the hypothesis that restoring a youthful signal might restore a youthful repair response. ### Why does GHK decline with age? Plasma GHK falls from roughly 200 ng/mL at age 20 to about 80 ng/mL by age 60 [3]. The regeneration reviews treat this decline as a proposed contributor to the slower tissue repair seen with age, which is what motivates the anti-aging research interest. The figure is an observed plasma concentration, not a deficiency diagnosis or a dosing target. ### What is the GHK-Cu mechanism of action? GHK-Cu acts as a copper chaperone and a pleiotropic signaling molecule: at picomolar-to-nanomolar levels it stimulates fibroblast collagen, elastin and glycosaminoglycan synthesis, modulates MMPs against TIMPs, upregulates VEGF and FGF-2, and suppresses free radicals and inflammatory signaling [6]. The bound copper enables lysyl-oxidase cross-linking and antioxidant chemistry the free peptide does not reproduce [6]. ### What is GHK-Cu and how does it work? GHK-Cu is the copper(II) complex of the tripeptide glycyl-histidyl-lysine, naturally present in human plasma [3]. It works by delivering copper and a signal to fibroblasts and other cells, driving matrix synthesis, repair-gene expression and antioxidant defense [6]. The copper coordination is the part that does most of the documented work. ## Is GHK-Cu worth following? An honest summary of the questions The strongest stretch of this trail is topical dermatology; the thinnest is everything systemic. Below are the questions readers ask most often, answered in order, each marked to its study. The full set lives on the [frequently asked questions](/faq) page. ### Is GHK-Cu peptide really anti-aging? Research links GHK-Cu to anti-aging-relevant endpoints in cells and rodents: a genome-wide signature shifting expression toward repair and antioxidant programs, reduced senescence markers p21 and p53 in aged fibroblasts, and lower reactive oxygen species [2][15][7]. Human evidence remains limited to small topical skin trials, so the anti-aging label is best read as research-supported for skin and preliminary beyond it. ### Is GHK-Cu worth the hype? The topical skin-firmness and collagen literature is genuinely supportive — procollagen rose in 70% of GHK-Cu users versus 40% for retinoic acid in one review [3]. Much of the broader anti-aging claim rests on in-vitro and rodent data and a concentrated authorship base [2], so the honest verdict is promising-but-preliminary outside topical dermatology. ### What does a GHK-Cu peptide do? In research models it stimulates synthesis of collagen, elastin, glycosaminoglycans and decorin, supports angiogenesis and wound repair, and exerts antioxidant and anti-inflammatory effects via copper-dependent signaling [3][6]. The effects are consistent across many models; the open question is how completely they translate to humans by routes other than topical. ### What is the difference between GHK and GHK-Cu? GHK is the free tripeptide (MW 340.38, CAS 49557-75-7); GHK-Cu is the copper chelate (MW 402.92, CAS 89030-95-5) [3]. Copper coordination is required for most documented matrix-remodeling activity — the free peptide does not reproduce MMP-2 stimulation in fibroblast cultures — so the form a study used materially changes what its result means [3]. ### What are the downsides of copper peptides? Documented limitations include low topical bioavailability of the native peptide, incompatibility with vitamin C and low-pH acids, a localized-hyperpigmentation signal in some applications, and a theoretical copper-accumulation concern with prolonged systemic use [15][6]. No human copper-toxicity case attributed to GHK-Cu appears in the peer-reviewed record [6]. ### Does GHK-Cu affect inflammation? In research models GHK-Cu suppresses NF-kB-driven inflammation, lowers TNF-alpha and free radicals during tissue remodeling, and reversed an emphysema-related gene signature in human COPD lung fibroblasts, restoring fibroblast function toward non-diseased patterns [6][8]. The COPD work is in-vitro on patient-derived cells, not a clinical outcome. ### Is GHK-Cu safe for long-term use? Topical Copper Tripeptide-1 has a long cosmetic safety record, and the complex's high copper stability constant (log K around 16.4) limits free-copper release [6]. There is no validated long-term human safety or pharmacokinetic data for injectable or systemic use, which remains research-only [3]. ### Can GHK-Cu help with wound healing? Wound-repair reviews report GHK-Cu increases collagen, elastin, VEGF, FGF-2 and neurotrophins while chemoattracting repair cells [6]. In rodent models a biotinylated-GHK collagen matrix accelerated dermal wound healing [12]. The data are predominantly animal and in-vitro, which is the honest boundary of this claim. The regulatory line is the same across every page: there is no FDA- or EMA-approved therapeutic indication for GHK-Cu by any route, topical Copper Tripeptide-1 is a legal cosmetic ingredient, and injectable or systemic use is unapproved and research-only [3]. See the [GHK-Cu safety and regulatory status](/faq) and the [full reference list](/references). --- An expedition map of the GHK-Cu copper-peptide literature — each study set down as a waypoint and each missing stretch of human data marked as a river to ford, guiding no patient and dispensing nothing.